Transcriptomic Study of Cutaneous Fibroblasts in Scleroderma

Recruiting Observational Study
Scleroderma
No Placebo Group Every participant receives an active treatment — no one gets a placebo. Healthy Volunteers Welcome You do not need to have the condition being studied to take part. No Study Drug Researchers observe your health over time — no experimental treatment is given.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 and older
Sex
Any
Study type
Observational
Participants needed
60 (estimated)
Sponsor
Centre Hospitalier Universitaire Dijon · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
Scleroderma is a complex connective tissue disease involving three interconnected pathophysiological axes: vascular hyperactivity and remodelling, immune system dysfunction and over-activation of fibroblasts at the origin of the fibrosis process in the skin and organs. Given that this pathology occurs preferentially in mature subjects, it is possible to suggest a potential inductive role for senes…
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: FOR PATIENTS WITH SCLERODERMA : * Person who has given written consent * Person with systemic scleroderma FOR CONTROL PARTICIPANTS : * Person who has given written consent * Person undergoing plastic, cosmetic and reconstructive surgery Exclusion Criteria: FOR PATIENTS WITH…
Contacts

Bernard BONNOTTE

03.80.29.34.32

Bernard.bonnotte@chu-dijon.fr

CONTACT